Press Releases

Date Title View
Toggle SummaryMay 27, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 11, 2020 GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 6, 2020 GenMark Prices Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 6, 2020 GenMark Commences Public Offering of Common Stock
CARLSBAD, Calif. , May 06, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 4, 2020 GenMark Diagnostics Reports First Quarter 2020 Results
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. ("GenMark" or the "Company") (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended March 31, 2020 .
View HTML
Toggle SummaryMay 4, 2020 GenMark Diagnostics Announces Scott Mendel Appointed CEO
CARLSBAD, Calif. , May 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel has been appointed President and Chief Executive Officer effective immediately.
View HTML
Toggle SummaryApril 22, 2020 GenMark Diagnostics to Report First Quarter 2020 Financial Results on May 4, 2020
CARLSBAD, Calif. , April 22, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its first quarter earnings results after market close on Monday, May 4, 2020. Management will hold a conference call to review the company's financial performance
View HTML
Toggle SummaryApril 7, 2020 GenMark Diagnostics Provides Preliminary Financial and Operational Results for First Quarter 2020 and Increases 2020 Revenue Guidance
First Quarter 2020 Revenue Expected to Represent Approximately 80% Year-Over-Year Growth CARLSBAD, Calif. , April 07, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
View HTML
Toggle SummaryMarch 23, 2020 GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel
CARLSBAD, Calif. , March 23, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority (BARDA), part
View HTML
Toggle SummaryMarch 19, 2020 GenMark Receives FDA Emergency Use Authorization for its ePlex® SARS-CoV-2 Test
COVID-19 diagnosis in under two hours now available globally in hospitals on company’s ePlex System Unique sample-to-answer capability enables near patient testing for the most critical patient populations CARLSBAD, Calif. , March 19, 2020 (GLOBE NEWSWIRE) --   GenMark Diagnostics, Inc.
View HTML